NSCLC

[eFFECTOR Therapeutics, Inc.] eFFECTOR Therapeutics, Inc. announced the initiation of dosing in the Phase IIa expansion portion of an ongoing Phase I/II trial of zotatifin in solid tumors. eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer.

[Cell Death Discovery] Scientists examined the potential roles of RAS-associated domain family 9 in non-small cell lung cancer and the underlying mechanisms.

[Aging] Scientists investigated the effects of autophagy-inducing agent, Rapamycin, combined with the histone deacetylase inhibitor, Suberoylanilide Hydroxamic Acid, on the radiosensitivity of A549 and SK-MES-1 cells, and examined the combination effects on DNA damage repair, and determined the level of autophagy and acetylation in A549 cells.

[Cancer Discovery] The authors describe the molecular and clinicopathologic features of EGFR ins20 mutations and summarize recent data on emerging therapies for patients with this subtype of EGFR-mutant non–small cell lung cancer (NSCLC).

[HUTCHMED Limited] HUTCHMED Limited and AstraZeneca PLC have initiated a Phase II study of ORPATHYS®, an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction.

[Cell Death & Disease] Researchers investigated the role of exosomal miR-1260b derived from non-small cell lung cancer in tumor progression.